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Abstract
Introduction: Two self-expandable stents, the Neuroform and the Enterprise stent, are widely used for stent-assisted coiling
(SAC) of complex shaped intracranial aneurysms. However, comparative knowledge about technical feasibility, peri- and
post-procedural morbidity and mortality, packing densities as well as follow-up data is limited.
Material and Methods: We conducted a retrospective study to investigate differences in aneurysms stented with the
Enterprise or Neuroform stents. Angiographic follow-up (mean 19.42 months) was available in 72.6% (61/84) of aneurysms
treated with stent-assisted coiling. We further sought to compare stent-assisted coiling to a matched patient population
with aneurysms treated by conventional coil embolization.
Results: The stenting success rate of the Enterprise was higher compared to the Neuroform stent (46/48 and 42/51,
respectively). In 5 of 9 cases in which the Neuroform stent was not navigable to the landing zone, we successfully deployed
an Enterprise stent instead. Eventually, 42 aneurysms were coiled after stenting in each group. We observed no significant
differences in peri-procedural complication rate, post-procedural hospital stay, packing density, recurrence rate or number
of in-stent stenosis. Strikingly, 36.1% of followed aneurysms in the SAC group showed progressive occlusion on
angiographic follow-up imaging. The packing density was significantly higher in aneurysms treated by SAC as compared to
conventionally coiled aneurysms, while recanalization rate was significantly lower in the SAC group.
Conclusion: The procedural success rate is higher using the Enterprise, but otherwise both stents exhibited similar
characteristics. Lower recurrence frequency and complication rates comparable to conventional coil embolization
emphasize the importance of stent-assisted coiling in the treatment of complex aneurysms. Progressive occlusion on
angiographic follow-up was a distinct and frequent observation in the SAC group and may in part be due to flow diversion.
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Introduction
Stent-assisted coiling (SAC) allows endovascular treatment of
complex shaped and wide necked intracranial aneurysms, which
are challenging for conventional coil embolization (CCE).
Currently, two stents are approved for SAC in the USA, the
Enterprise Vascular Reconstruction device (Enterprise, EP) (Cod-
man Neurovascular/Johnson & Johnson) and the Neuroform stent
(NF) (Boston Scientific).
Prior reports have tabulated the procedural feasibility, morbid-
ity and mortality associated with each stent individually. There is a
wide range of results reported for each stent regarding several
outcomes, including stenting success rate, initial grade of occlusion
and complication rates [4,8,9,13,18]. An interpretation of data
gathered from different centers using either stent or differences
between the two available stents may therefore be difficult.
Although both stents are frequently used for SAC, mid-term
results associated with either stent are restricted to a relatively
small number of studies with angiographic follow-up durations of
up to 6.9 months for the EP [7,8] and 4.6 to 12.1 [9–14] months
for the NF, and long-term follow-up experience is scarce [15,16].
The packing density is defined as the ratio between the volume
of coils inserted into the aneurysm and the aneurysm volume. In
conventional coil embolization a high packing density is associated
with lower recurrence and retreatment rates [1,2]. Experimental
aneurysm embolization with Enterprise stent assistance was shown
to achieve higher packing densities than aneurysms coiled without
prior stent placement [3]. However, it is unclear whether SAC
provides a clinical advantage with respect to achieving higher
packing densities and how packing densities influence recurrence
rates.
Previous studies reported that aneurysms with remaining flow
into the aneurysm sac after initial treatment were found to have
higher occlusion grades on follow-up imaging. This process, also
known as progressive occlusion is associated with reduced blood
flow in the sac of aneurysms as observed in studies using flow
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treated with the Neuroform stent indicating that flow diversion
may also contribute to delayed aneurysm occlusion in SAC in the
mid-term follow-up [6].
The goal of this single-center study was to evaluate several
parameters in the comparison of the Neuroform and Enterprise
stents in stent-assisted coiling and related midterm follow-up
findings. We further put these results into the context of
conventional coil embolization of intracranial aneurysms.
Materials and Methods
Patients and aneurysm treatment
Under institutional review board approval, we retrospectively
analyzed the imaging and medical charts of 356 consecutive
patients with 385 aneurysms coiled between November 2001 and
February 2010. 270 patients harboring 292 aneurysms were
treated with conventional coil embolization. 86 patients with 93
aneurysms were intended to be treated by stent-assisted coiling of
which 84 aneurysms (n=42 using the Neuroform and n=42 using
the Enterprise stent) were coiled after successful stent-placement.
Five aneurysms, which initially failed treatment with Neuroform
(NF), were eventually stented using the Enterprise stent (EP).
Stent-assisted coiling was performed in aneurysms with a dome-to-
neck ratio ,2 or a neck diameter .4 mm and in complex shaped
aneurysms that were not approachable by conventional coil
embolization. Aneurysms were either coiled with the jailing
technique (with NF or EP) or coiling was performed after
placement of the stent by taking advantage of the open cell design
of Neuroform stents.
Surgical procedure and perioperative medication
Coiling in all patients was performed under general anesthesia
approach in a sterile environment using a common femoral artery
approach (except for two brachial) and full anticoagulation with
heparin. Heparin anticoagulation was delayed until placement of
the initial coil in ruptured aneurysms. The activated clotting time
was kept at 250 or higher during all procedures. In unruptured
aneurysms treated with SAC, the patients received a dual anti-
platelet therapy, including 75 mg of clopidogrel and 325 mg of
aspirin for 5 days before stent placement, and dual anti-platelet
therapy for 6 months following the procedure. In ruptured
aneurysms treated with SAC, the patients received a weight-
adjusted bolus dose of abxicimab (ReoPro, 0.25 mg/kg intrave-
nous bolus) at the time of stent deployment followed by 150 mg of
clopidogrel and 650 mg of aspirin 12 hours later, and followed by
75 mg of clopidogrel and 325 mg of aspirin daily. Ventricular
drains were placed prior to SAC interventions in the cases of
ruptured aneurysms.
Data collection and statistical analysis
In addition to clinical presentation and patient demographics,
data was collected for aneurysm size, location, shape (ellipsoid vs.
spherical), orientation (sidewall vs. bifurcation), morphology
(fusiform vs. saccular), packing density, rupture status and
periprocedural morbidity and mortality. In order to put the
SAC results into the context of conventional coil embolization, we
used the optmatch package (version 0.7–1) of the R tool (version
2.12.1, http://cran.r-project.org) to match patients with aneu-
rysms treated by conventional coil embolization to patients treated
by SAC. The aneurysms were matched regarding patient age and
gender, aneurysm size, localization, orientation as well as the
aneurysm rupture status. Pearson’s Chi square and Fisher’s exact
test were determined for demographic and contingency differen-
tiation. Student’s t test was used to determine statistical
significance in continuous scaled parameters, including age,
packing density, post-procedural hospital stay and aneurysm size.
Ap ,0.05 was considered statistically significant.
SAC procedure success evaluation
All treated aneurysms were graded independently by two
experienced interventional neuroradiologists using several views
for each treated aneurysm, including 3-dimensional angiography.
Assessment of the degree of aneurysm occlusion was evaluated as
complete occlusion (OG1), neck remnant (OG2) and residual filing
of the aneurysm sac (OG3) [2]. Angiograms were further assessed
for in-stent stenosis or thrombosis and stent migration. Inter-rater
agreement was indicated by the Cohen’s Kappa (K).
Packing density
Aneurysm packing percentage was calculated as coil volume
divided by aneurysm volume. Coil volume was calculated by
summing individual coil volumes as indicated by their manufac-
turers. Aneurysm dimensions were measured by 3-dimensional
images derived from rotational angiography. Because aneurysm
volume exhibit meaningful variation depending on the calculation
method, we classified aneurysms based on their shape into either
ellipsoids or spheroids. Aneurysms with a dome-to-neck length
(=height).1.56 diameter or diameter .1.56 height were
designated as ellipsoids, all others were designated as spheres.
Follow-up protocol
Immediate post-treatment angiographic images were compared
to similar projection follow-up images. A conventional angiogra-
phy was obtained in all but five cases where magnetic resonance
angiography or computed tomography angiography of diagnostic
quality was obtained. The standard follow-up protocol included an
angiography within 6 months after endovascular treatment, a
second angiography after 1 year, and a third and fourth being
performed 2 and 3 years post-treatment, respectively. In the
absence of recanalization, further follow-up occurred in 2 year
intervals. In the case of recurrence or additional untreated
aneurysms, patients were retreated/treated when necessary and
followed according to the same scheme. Patients were assessed
immediately after the procedure and a neurological exam was
performed at follow-up visits prior to imaging. Major neurological
complications were defined as Glascow Outcome Score (GOS),5.
Results
Characteristics of treated aneurysms
93 aneurysms in 86 patients qualified for treatment by SAC. Of
the aneurysms intended to be treated by SAC, 84 (42 EP and 42
NF, respectively) were successfully stented and subsequently coil
embolized (Table 1). 67% of the aneurysms were located in the
anterior and 33% in the posterior circulation (Table 2). The mean
aneurysm size was 7.43 mm (63.13) in the EP and 7.6 mm
(62.35) in the NF group. 13 aneurysms stented by EP had
fusiform morphology and 29 were saccular, while 13 were fusiform
and 29 had saccular morphology in the NF group. A total of 7
ruptured aneurysms (8.33%), 3 in the EP group and 4 in the NF
group were treated by SAC). More sidewall aneurysms (29 EP and
33 NF) than bifurcation aneurysms (13 EP and 9 NF) were treated
by SAC.
The majority of aneurysms were discovered incidentally (48/90)
followed by aneurysms that were previously discovered, and
aneurysms that became clinically apparent, most frequently due to
cranial nerve compression symptoms and headache.
Neuroform vs. Enterprise Stent
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Navigation and subsequent deployment of the Enterprise stent
was significantly more often successful as compared to using the
Neuroform stent (p=0.0329) (Figure 1).
Of the 51 aneurysms intended to be treated by SAC using the
NF, 42 (82.3%) were successfully stented and coiled by the jailed-
catheter technique in all but in one cases. In this patient, the stent
was deployed over the aneurysm neck after a previously placed coil
prolapsed into the parent artery. In two patients, a single stent
sufficiently covered the neck of 2 aneurysms. In 8 cases the NF
stent could not be navigated to the desired landing zone and had
to be removed. Six of these were located in the anterior circulation
(2 ophthalmic segment ICA, 1 terminal ICA, 1 posterior
communicating artery, 1 supraclinoid ICA and 1 in the cavernous
ICA) and 2 in the posterior circulation (1 posterior cerebral artery,
and 1 in the vertebrobasilar junction). Inability to navigate the NF
to the landing zone was associated with tortuosity of the
vasculature. Furthermore, we had one case, in which a Neuroform
stent expanded unplanned in the ICA.
In 6 cases where the NF was not navigable, we attempted to
place an EP instead. The EP was successfully navigated in all 6
cases and deployed in 5 cases. Subsequent coiling was performed
without complications. In the remaining case, the operator
decided not to deploy the EP stent due to high resistance.
Of the 48 aneurysms, including the above mentioned 6 cases,
intended to be treated with the EP, the stent was successfully
navigated and deployed in 46 (95.8%). In two patients, one EP
covered two adjacent aneurysms and in an 81 year old patient with
a ruptured side-wall basilar aneurysm, two stents were used to
cover one aneurysm. In 42 (91.3%) aneurysms subsequent coiling
was performed in the same session.
Procedure related morbidity and mortality
We observed no significant differences in peri-procedural
morbidity and mortality between both stents. Procedure related
morbidity with long-term neurological sequela (GOS=3) was 1
(1.9%) in 51 cases in which the NF was placed or intended to be
placed. In the EP group, the treatment of 2 (4.2%) aneurysms was
Table 1. Baseline Demographics of aneurysms treated by stent-assisted coiling using the Enterprise or Neuroform stent.
Enterprise Neuroform
T-Test
(p-value)
Likelihood
ratio (p-value) OR 95% CI
Age (years±SD) 55.2611.65 56.7611.84 0.5377
Gender (f/m) 38/4 37/5 1 0.772 0.106–4.91
Mean max dimension (mm±SD) 7.4363.13 7.662.35 0.7812
localization (ant/post) 28/14 29/13 1 0.898 0.324–2.475
Orientation (SW/Bifurcation) 29/13 33/9 0.457 0.612 0.199–1.811
Morphology (saccular/fusiform) 29/13 29/13 1 1 0.358–2.796
Shape (sphere/ellipsoid) 36/6 33/9 0.57 1.627 0.459–6.2
Unruptured/Ruptured 39/3 38/4 1 1 0.233–4.293
Packing density (%±SD) 35.99622.96 37.96622.9 0.8096
Recurrence (present/absent) 4/26 3/28 0.707 1.427 0.218–10.685
Numbers refer to aneurysms that were eventually coiled by stent assistance (n=42 with Neuroform and n=42 with Enterprise). Abbreviations: f (female), m (male), mm
(millimeters), ant (anterior circulation), post (posterior circulation), SW (side wall), SD (standard deviation), OR (odds ratio), CI (confidence interval).
doi:10.1371/journal.pone.0024875.t001
Table 2. Location and mean maximum diameter of aneurysms stented using either the Enterprise or Neuroform stent and
subsequently treated by coiling.
SAC (n=) Enterprise (n=) Mean dimension (mm) Neuroform (n=) Mean dimension (mm)
ICA cavernouse segment 9 4 7,75 5 8,28
ICA ophthalmic segment 36 18 7,49 18 7,73
ICA supraclinoid segment 5 3 8,83 2 8,2
MCA 10 1 4 , 5
AC 43 7 , 8 1 5
PC 2 0 2 8,35
Basilar apex 18 10 7,37 8 7,54
Basilar trunk 10 1 6
Vertebral artery 32 8 , 1 1 7
SCA 22 5 , 8 0
PICA 3 0 3 7,03
Total (n=) 84 42 42
Abbreviations: SAC (stent-assisted coiling), n (number of aneurysms), mm (millimeters), ICA (internal carotid artery), MCA (middle cerebral artery), AC (anterior
communicating artery), PC (posterior communicating artery), SCA (superior cerebellar artery) and PICA (posterior inferior cerebellar artery).
doi:10.1371/journal.pone.0024875.t002
Neuroform vs. Enterprise Stent
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cations (GOS=4 in both cases). Most minor and major peri-
procedural complications observed in this study were related to
anti-platelet therapy and thromboembolism (Table 3). Minor
procedure related events, such as groin hematoma, iliac
hematoma and headache occurred in 7 patients (3 in the EP
and 4 in the NF group).
There was 1 death in the group of patients stented with a NF.
The 71 year old patient was treated for a paraophthalmic ICA
aneurysm and tolerated the procedure without problems, but
suffered from an intraparenchymal hemorrhage while on dual
anti-platelet medication. We also observed 1 death in the patient
group treated with the EP. The 81 year old patient presented with
a ruptured 2.3 mm basilar sidewall aneurysm. During attempted
microcatheter access the aneurysm re-ruptured. Although a
second stent was deployed across the aneurysm neck, the patient
eventually died due to complications of a SAH-related vasospasm.
The procedure related morbidity and mortality of patients
treated with SAC was comparable to the matched patient group
receiving conventional coil embolization (p.0.05).
In 61 (71.2%) cases, patients were discharged from hospital 1
day after the SAC. Mean post-procedural hospital stay in the NF
group was 1.63 days vs. 4.77 days in the EP group, but was not
statistically significant (p=0.0871). Median post-procedural hos-
pital stay was 1 day in both groups.
Initial angiographic results and delayed aneurysm
occlusion in SAC
Angiographic results were evaluated independently by two
raters. There was substantial agreement in the reading results
(k=0.652). On the immediate post-treatment angiogram the
occlusion grade was as follows for the Enterprise group (Table 4):
OG1 in 13 (30.95%), OG2 in 16 (38.1%) and in OG3 13 (30.95%)
aneurysms; in the Neuroform group we observed OG1 in 18
(42.8%), OG2 in 17 (40.5%) and OG3 in 7 aneurysms (16.67%).
Angiographic follow-up imaging was available for 61 aneurysms
(30 EP and 31 NF).
The degrees of occlusion in followed aneurysms treated with EP
were: OG1 in 15 (50%), OG2 in 11 (37.67%) and OG3 in 3
(13.3%); occlusion grades in the NF group were: OG1 in 15
(48.4%), OG2 in 12 (38.7%) and OG3 in 4 (12.9%) aneurysms.
Thus, 22 of 61 (36.1%) followed aneurysms underwent delayed
occlusion of the aneurysm sac. The frequency of aneurysms with
OG3 flow into the sac decreased from 23.8% on initial angiogram
evaluation to 13.1% on the final available follow-up, while the
overall frequency of aneurysms with complete sac occlusion
increased from 36.9% to 49.1% (Table 4). A representative case for
each stent is shown in Figure 2 and Figure 3.
Logistic regression analysis revealed that sidewall aneurysms
(p=0.0009) and localization in the anterior circulation
(p=0.0464) favored delayed occlusion of the aneurysm. Progres-
sive occlusion was independent from the aneurysm size and
packing density.
Furthermore, we observed partial coil prolapse into the parent
vessel in two aneurysms treated with the NF and two in the EP
group.
Packing density
We observed no significant difference in packing density
comparing the NF and EP group (p=0.8096). However, the
packing density in the SAC group was clearly higher compared to
the CCE group (mean 36.59% vs. 28.58%, p=0.0189) (Table 5).
Overall, lower packing density was associated with large aneurysm
size (p,0.0001) and ellipsoid aneurysm morphology (p=0.0056).
Recurrence rates and time to angiographic recurrence
Aneurysm recanalization rates were comparable for both stents,
with 3 occurring in the NF and 4 in the EP group (p=0.707).
Overall, the recurrence rate was lower in aneurysms treated with
SAC as compared to the CCE treatment (11.5% vs. 28.5%;
p=0.014). Mean time to angiographic recurrence was 318 days in
the CCE group and 208 days in the stented group (p=0.2408).
Anterior circulation aneurysms were associated with a longer time
period to recurrence in the CCE group (p=0.0271), but not in the
SAC group (p=0.7765).
Interestingly, lower packing density was linked to a higher
recurrence rate in the CCE group (p=0.0299), but not in the SAC
group (p=0.4648). The mean packing density determined in
recanalized aneurysms was 22.95% in the CCE group vs. 30.53%
in the SAC group.
Follow-up findings
Conventional angiographic follow-up was available for 61
(72.6%) aneurysms treated with SAC with a mean follow-up time
Figure 1. Flow chart of aneurysms treated by stent-assisted coiling.
doi:10.1371/journal.pone.0024875.g001
Neuroform vs. Enterprise Stent
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24875of 19.42 months (14 months in the EP, 25 months in the NF
group). In the EP group, one asymptomatic stent migration was
discovered at 20 month follow-up angiogram for a basilar apex
aneurysm. One in-stent stenosis occurred in the EP group
discovered 11 weeks after SAC in a 46 year old female with a
saccular aneurysms located in the cavernous ICA segment. The
stenosis remained stable and the patient was asymptomatic at 6
months follow-up evaluation. Two cases of in-stent stenosis
occurred in the NF group. The first resulting in an ipsilateral
stroke occurring 6 weeks after SAC in a patient with thrombo-
cytopenia related bleeding that required stoppage of anti-platelet
therapy. The second case was discovered 8 weeks after EVT in an
asymptomatic patient and was stable as of 55 months follow-up
angiography.
Discussion
Self-expanding stents are frequently used in the coiling of wide-
necked and fusiform intracranial aneurysms. However, the
clinical impact of available stents and delivery systems remains
scarce as indicated by a large meta-analysis [17]. Prior studies
have outlined the characteristics of the Neuroform stent,
including the stenting success rate, complication rates in ruptured
and unruptured aneurysms and in-stent stenosis rates [7,9,11–
13,18–21], while comparatively little published regarding the
Enterprise stent [8,22]. There is limited evidence about
comparative benefit of using one of the two FDA approved
stents for SAC over the other. Knowledge about long-term results
with SAC is scarce [15].
Table 3. Periprocedural mortality and major complications in patients treated in the by stent-assisted coiling.
Patient age,
gender
aneurysm
localization
aneurysm
size (mm)
shape,
status stent complication Treatment
Long-term
neurological
deficit
45, f basilar apex 2 saccular,
ruptured
EP Rebleeding, hydrocephalus
requiring shunt placement
Surgical and
medical
absent
49, f basilar apex 29 fusiform EP Retroperitoneal hematoma
requiring transfusion and ICA
dissection requiring stenting
Medical present
(GOS=4)
59, m vertebral artery 7 fusiform EP brachial pseudoaneurysm Conservative absent
41, m ophthalmic ICA 9 saccular EP Thrombembolism;
vision impairment
Medical present
(GOS=4)
55, m ophthalmic ICA 10 fusiform,
ruptured
NF Cardiac arrest Medical absent
56, f ophthalmic ICA 9.4 saccular NF Thromboembolism Medical present
(GOS=3)
57, f cavernous ICA 25 fusiform NF Thromboembolism
(small ICA thrombus)
Medical absent
77, f ophthalmic ICA 6.6 saccular NF Epidural hematoma
after fall
Conservative absent
51, f basilar apex 9 fusiform NF Retroperitoneal hematoma
requiring transfusion
Medical absent
90 days mortality Cause
71, f ophthalmic ICA 5 saccular NF Anti-platelet treatment
related ICH
81, f basilar apex 2.5 saccular,
ruptured
EP Hemorrhage
(rebleeding)
Abbreviations: f (female), m (male), mm (millimeters), EP (Enterprise stent), NF (Neuroform stent), ICA (internal carotid artery), ICH (intracerebral hemorrhage), GOS
(Glascow Outcome Score).
doi:10.1371/journal.pone.0024875.t003
Table 4. Initial angiographic outcome of aneurysms coiled with stent-assistance using the Neuroform or Enterprise stent and
occlusion grade at final angiographic follow-up.
Occlusion grade at SAC Occlusion grade at final follow-up
OG1 (n) OG2 (n) OG3 (n)
FU available
(n)
Mean FU
(months) OG1 (n) OG2 (n) OG3 (n)
Enterprise 30.95% (13) 38.1% (16) 30.95% (13) 30 14 50% (15) 36.67% (11) 13.3% (4)
Neuroform 42.8% (18) 40.5% (17) 16.67% (7) 31 25 48.4% (15) 38.7% (12) 12.9% (4)
Total SAC 36.9% (31) 39.3% (33) 23.8% (20) 61 19.42 49.1% (30) 37.7% (23) 13.1% (8)
Abbreviations: OG1 (complete occlusion), OG2 (neck remnant), OG3 (saccular filling), n (number of aneurysms), FU (follow-up), SAC (stent-assisted coiling).
doi:10.1371/journal.pone.0024875.t004
Neuroform vs. Enterprise Stent
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allowed a good comparison of the stents. Both stents possessed
good to excellent procedural feasibility (82% NF, 96% EP) in close
agreement with previously reported success rates of 84 to 90% for
the Neuroform and 90 to 100% for the EP [7–9,11–14,18–21].
However, the success rate was clearly higher in the Enterprise
group and in 5 of 6 cases where the NF could not be placed the EP
was successfully deployed.
Both stents were associated with a comparably low peri-
procedural complication rate and mortality. In contrast to a large
study [4] and despite the more complex morphology of aneurysms
treated by SAC, there was no significant difference in peri-
procedural morbidity with long-term neurological sequela and
mortality between the SAC using either stent and the CCE group.
As outlined by the authors, the alarmingly high complication rate
of 7.8% in the SAC group may be biased due to the use of balloon
mounted stents [4] as compared to self-expandable stents, such as
the Neuroform and Enterprise stent. However, the complication
rate observed in this study is consistent with other studies ranging
from 0 to 16% [8,9,11,12,14,18–23] determined in studies
including ruptured as well as unruptured aneurysms and between
4.9 to 24% [7,13] in studies with ruptured aneurysms only.
Mortality rates in studies including mainly unruptured aneurysms
ranged from 0 to 4.6% [8,9,12,18,19,21,22] and 0 to 20%
[11,13,14] in reports with a high number of or only ruptured
aneurysms. Long-term neurological complications occurred in
3.5% of patients treated with SAC and were linked to hemorrhage
while on dual anti-platelet therapy and to a lesser degree due to
Figure 2. A 45 year old woman presented with double vision and subsequent angiographic imaging revealed bilateral aneurysms
of the ICA of which one was located in the right paraophthalmic ICA measuring 4.2 mm. Figure 2A shows the aneurysm in the lateral view
before treatment and immediately after stent-assisted coiling using a 4.5622 mm Enterprise stent (B). Residual flow to the neck of the saccular
aneurysm was noted on immediate post-treatment angiography. The 10 months follow-up imaging (C) revealed that the aneurysm underwent
progressive occlusion as there was no residual flow visible while the aneurysm displayed satisfactory coil coverage.
doi:10.1371/journal.pone.0024875.g002
Figure 3. A 64 year old woman presenting with vision impairment was found to have an aneurysm measuring 5 mm that was
located in the supraclinoid ICA segment. Pre-treatment angiographic imaging (A and B) revealed a saccular wide-necked aneurysm which was
accessible by SAC. A Neuroform stent was successfully navigated, deployed and subsequent coiling was performed. Immediate post-treatment
results (C and D) demonstrated only partial occlusion of the aneurysm and flow beyond the aneurysm neck was present. At 6-months follow-up
imaging (E) no residual flow into the aneurysm sac was detectable. These results were stable at 18-months follow-up imaging (F) and emphasize the
potential of aneurysms to undergo progressive occlusion after treatment by stent-assisted coiling.
doi:10.1371/journal.pone.0024875.g003
Neuroform vs. Enterprise Stent
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from hemorrhage. One from aneurysm rupture during coiling and
the second from a large cortical hematoma that occurred while still
on dual anti-platelet therapy. Bleeding episodes occurred with
higher frequency early in our experience with SAC and we
subsequently reduced the time on dual-anti-platelet therapy from 6
month to 6–12 weeks after SAC. However, bleeding facilitated by
dual anti-platelet therapy after stent-assisted treatment remains a
concern.
In this study, packing density in the SAC group was higher
compared to the CCE group (36.59% vs. 28.58%). Although an in
vitro study indicated that packing density was 10.5% higher in
aneurysms coiled with stent assistance, this is the first report
confirming this result in vivo. Furthermore, we show that not only
the EP, which was used in the in vitro study, but also the NF
achieved substantially higher packing densities, while no differ-
ences in packing densities were observed between both stents.
Recanalization rates using either stent were similarly low.
However, we observed significantly lower recurrence rates in the
SAC versus CCE group. High packing density was associated with
lower recurrence rates in the CCE group, which is consistent with
previous reports [1,4]. However, although packing was higher in
the SAC group, it had no impact on recurrence rates in this
aneurysm set. This observation was further supported by the
observation that the mean packing density in recurrent aneurysms
in the CCE was low (23%) [1], but relatively high (31%) in the
SAC group. Although controversial, hemodynamic flow changes
and redirection of forces induced by placing a stent over the
aneurysm neck may have a synergistic effect with coil packing of
the aneurysm. This unexpected finding may indicate that high
packing densities, although desirable, may not be necessary to
adequately occlude some aneurysms with SAC as suggested by
previous reports [4,9,15].
Initial angiographic results showed that 76.2% of aneurysms
treated with stent-assistance had total flow cessation or only
minimal flow into the neck (Table 4), which is consistent with
previous reports [4,9,15,22]. However, 92% of followed aneu-
rysms showed no flow or only minimal into the aneurysms, thus,
more than 36% of followed aneurysms showed progressive
occlusion. Sidewall orientation, anterior localization, good initial
coil coverage influenced delayed occlusion of the aneurysm. Again,
progressive sac occlusion was independent from the aneurysm
packing density and no major differences were found between
both stents. The lower frequency of delayed aneurysm occlusion in
the posterior circulation may be related to the fact that most of
these aneurysms were bifurcation aneurysms of the basilar apex.
The existing stent designs appear to influence bifurcation
aneurysm occlusion and thrombosis to a lesser degree.
Both available stents appear to have low rates of in-stent stenosis
indicating a good mid-term safety using either stent. Two cases of
in-stent stenosis were observed in the NF group, one was detected
in the EP group. It is unlikely that differences in length of follow-
up for the two stent groups influenced this difference as the stenosis
all occurred within 11 weeks following SAC. Spontaneous
migration of the EP was previously reported [24] and was seen
in one case occurring in a basilar apex aneurysm.
In conclusion, this study shows that the Enterprise stent is more
deliverable than the Neuroform stent, but both devices are feasible
and safe in use for the treatment of intracranial aneurysms while
exhibiting similar immediate and mid-term results. The major
neurologic morbidities and mortality compare favorably with CCE
and are low.
Although, both stents achieved high packing densities, neither
was the low recanalization rate nor the frequently observed
progressive aneurysm occlusion affected by packing. Thus,
hemodynamic flow changes facilitated by the placement of self-
expandable stents may contribute to successful treatment and long
lasting aneurysm occlusion as indicated for recently developed
flow diverter stents.
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